VivoSeq
Infectious Disease

CMV Infection

0

Pipeline Programs↗

3

Active Trials↗

0

Companies Involved↗

CMV Infection is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Unknown status6 · 43%
Completed5 · 36%
Recruiting2 · 14%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT
Recruiting·—·N/A·NCT06306989·150 enrolled
CMV CTLs in Neonates With CMV Infection
Recruiting·NNew York Medical College·Phase 2·NCT05564598·23 enrolled
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Not yet recruiting·NNew York Medical College·Phase 3·NCT07225972·69 enrolled
Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
Completed·TThe First Affiliated Hospital of Soochow University·N/A·NCT05789615·200 enrolled
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
Completed·UUniversity Hospital, Bordeaux·Phase 2·NCT04934527·42 enrolled
The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
Completed·MMayo Clinic·Phase 3·NCT00275665·20 enrolled
CMV-CTL for the Treatment of CMV Infection After HSCT
Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT03004261·5 enrolled
Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection
Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2/3·NCT00881517·124 enrolled
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
Unknown status·—·Phase 1·NCT05089838·12 enrolled
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06021210·80 enrolled
MSC for Treatment of CMV Infection
Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT02083731·120 enrolled
CMV-TCR-T Cells for CMV Infection After Allogenic HSCT
Unknown status·—·Phase 1·NCT05140187·12 enrolled
Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China
Unknown status·—·Phase 1·NCT02456610·30 enrolled
Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT
Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT05914701·31 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)